Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sleeping pill claims disturb NAD

This article was originally published in The Tan Sheet

Executive Summary

Urban Nutrition agrees to discontinue certain ad claims for its RestAid dietary supplement, including reference to the product as a "non-prescription sleeping pill," following a NAD review. The decision released Oct. 19, under NAD's CRN-supported work, concludes claims in print and online ads suggesting the product helps consumers fall asleep faster and deeper - and allows them to awake more refreshed - were unsupported by evidence in the record. Rather, NAD recommends limiting such claims to the product's melatonin ingredient. Further, the CBBB division found no evidence to support the claim the product's delivery system "gets the nutrients into the bloodstream much quicker than other supplements." New York-based Urban Nutrition, which agreed to modify its ads, previously was the subject of an Electronic Retailing Self-Regulation Program review that found the firm failed to disclose its material connection to products it endorsed on a review website it operated (1"The Tan Sheet" Aug. 17, 2009, In Brief)

You may also be interested in...

ERSP calls for Web disclosures from Urban Nutrition

The operator of and other Web sites should clarify that it markets weight-loss supplement MiracleBurn - featured as the "most popular" product and a "customer choice award" winner on the site - according to the Electronic Retailing Self-Regulation Program. Urban Nutrition presented as a review forum for diet products, though a challenger argued to ERSP that the site "is premised on a deliberate intent to mislead consumers" by disguising ads as independent product reviews. The CBBB program recommended Aug. 11 that the firm disclose its material connection to the products it endorses. New York-based Urban Nutrition said it will "follow the ERSP's recommendations to reinforce several aspects of effective disclosure methods.

Neuroscience Challenges Oncology For Top Spot In CDER’s 2019 Novel Approvals

Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.

In Case You Missed It … News On China Patents, EMA Chief, And More

We clean out your Martin Luther King Day inbox so you don't have to.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts